Voith B - Search Results

1

A mechanistic approach for the scaling of clearance in children.

Edginton AN, Schmitt W, Voith B, Willmann S. Edginton AN, et al. Among authors: voith b. Clin Pharmacokinet. 2006;45(7):683-704. doi: 10.2165/00003088-200645070-00004. Clin Pharmacokinet. 2006. PMID: 16802850

2

Guidances related to bioavailability and bioequivalence: European industry perspective.

Ahr G, Voith B, Kuhlmann J. Ahr G, et al. Among authors: voith b. Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):25-7. doi: 10.1007/BF03190052. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11032085

3

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Mueck W, et al. Among authors: voith b. Int J Clin Pharmacol Ther. 2007 Jun;45(6):335-44. doi: 10.5414/cpp45335. Int J Clin Pharmacol Ther. 2007. PMID: 17595891 Clinical Trial.

4

The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.

Mück W, Park S, Jäger W, Voith B, Wandel E, Galle PR, Schwarting A. Mück W, et al. Among authors: voith b. Int J Clin Pharmacol Ther. 2001 May;39(5):192-8. doi: 10.5414/cpp39192. Int J Clin Pharmacol Ther. 2001. PMID: 11380064 Clinical Trial.

5

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.

Kubitza D, Becka M, Schwers S, Voith B. Kubitza D, et al. Among authors: voith b. Clin Pharmacol Drug Dev. 2013 Jul;2(3):270-7. doi: 10.1002/cpdd.26. Epub 2013 May 15. Clin Pharmacol Drug Dev. 2013. PMID: 27121789

6

First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone.

Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, Haynes RK, Kotecka BM, Rieckmann KH, Edstein MD. Nagelschmitz J, et al. Among authors: voith b. Antimicrob Agents Chemother. 2008 Sep;52(9):3085-91. doi: 10.1128/AAC.01585-07. Epub 2008 Jun 16. Antimicrob Agents Chemother. 2008. PMID: 18559649 Free PMC article. Clinical Trial.

7

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Kubitza D, et al. Among authors: voith b. Clin Pharmacol Ther. 2005 Oct;78(4):412-21. doi: 10.1016/j.clpt.2005.06.011. Clin Pharmacol Ther. 2005. PMID: 16198660 Clinical Trial.

8

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Kubitza D, et al. Among authors: voith b. Eur J Clin Pharmacol. 2005 Dec;61(12):873-80. doi: 10.1007/s00228-005-0043-5. Epub 2005 Nov 17. Eur J Clin Pharmacol. 2005. PMID: 16328318 Clinical Trial.

9

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grögler K, Herrmann V, Magin SG, Högemann A, Voith B, Mutschler E. Malerczyk C, et al. Among authors: voith b. Br J Clin Pharmacol. 1998 Jun;45(6):567-73. doi: 10.1046/j.1365-2125.1998.00722.x. Br J Clin Pharmacol. 1998. PMID: 9663812 Free PMC article. Clinical Trial.

10

Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.

Mück W, Frey R, Unger S, Voith B. Mück W, et al. Among authors: voith b. Int J Clin Pharmacol Ther. 2000 Jun;38(6):298-303. doi: 10.5414/cpp38298. Int J Clin Pharmacol Ther. 2000. PMID: 10890578 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results